Study of a new drug for relapsed or refractory non-hodgkin lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new oral drug called ICP-490 for people with non-Hodgkin lymphoma that has returned or not responded to standard treatments. The goal is to see if the drug is safe and effective in shrinking or controlling the lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have non-Hodgkin lymphoma that has come back or not responded to previous treatments.
- Your lymphoma must be measurable (i.e., visible on scans or tests).
- You must be reasonably active - able to care for yourself and do light activities.
- You must have adequately functioning organs (like liver and kidneys) and expected survival of at least 3 months.
- You must not have active lymphoma in the brain or spinal cord, or other active cancer in the past 3 years (except easily cured cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug (ICP-248) alone or with another antibody therapy for people with B-cell lymphomas that have returned or not responded to treatment. It aims to see if the drug is safe and if it can shrink or control the cancer.
This trial tests an experimental drug (HSK47977) to see how it works in people with non-Hodgkin lymphoma that has come back or not responded to treatment. The goal is to understand how the drug is processed by the body, its safety, and whether it can help shrink tumors.
This trial tests an experimental drug, SP-3164, for people with certain types of non-Hodgkin's lymphoma that have come back or not responded to prior treatments. The goal is to see if the drug can help shrink or control the cancer.
This trial tests a combination of three drugs (poseltinib, rituximab, and lenalidomide) for people with primary central nervous system lymphoma that has come back or not responded to earlier treatment. The goal is to see if this new mix can help control the disease.
This trial tests a new combination of drugs for people with a type of lymphoma (diffuse large B-cell lymphoma) that has come back or not responded to treatment. The goal is to see if this combination can help control the cancer.
This trial tests a new drug, LY4584180, for adults with several types of non-Hodgkin lymphoma who have already had at least two prior treatments. The goal is to see if the drug can help shrink tumors and stop the cancer from growing.
Hear when a new Relapsed or Refractory Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.